CHP
VKTX icon

Cable Hill Partners’s Viking Therapeutics VKTX Stock Holding History

Cable Hill Partners’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-1,000
Closed -$16K – 844
2018
Q3 		$16K Buy
+1,000
New +$11.9K 0.01% 352

Other funds holding VKTX

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
Fiera Capital (Canada)
Fiera Capital (Canada) Montreal, Quebec, Canada $29.2B AUM 20.16% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Cable Hill Partners's VKTX Position: Q2 2019 in Review

Cable Hill Partners sold out of Viking Therapeutics (VKTX) in Q2 2019, closing a stake of 4,000 shares — an estimated $40K sold.

Cable Hill Partners first reported a position in VKTX in Q3 2018 and held it in 3 quarters. The position peaked at $40K in Q1 2019. 156 funds tracked by Wall St. Rank hold VKTX as of Q2 2019.

  • Cable Hill Partners reported no remaining Viking Therapeutics position as of Q2 2019 after selling out during the quarter.
  • Cable Hill Partners sold 4,000 Viking Therapeutics shares in Q2 2019, an estimated $40K.
  • Cable Hill Partners first reported a position in Viking Therapeutics in Q3 2018 and held it in 3 quarters.
  • Cable Hill Partners's Viking Therapeutics position peaked at $40K in Q1 2019.
  • 156 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2019.

Based on Cable Hill Partners's 13F filing for Q2 2019, filed 6 Aug 2019.